The HER-2/neu gene and protein in breast cancer: Methods of detection and clinical significance

Journal of Clinical Ligand Assay

Volumn 23, Issue 1, 2000, Pages 21-32

  Ross, J S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Breast neoplasms; HER 2 neu; Prognosis; Proto oncogene cerbB2; Therapy

Indexed keywords

ARTICLE; BREAST CANCER; CANCER SURVIVAL; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; ONCOGENE C ERB; ONCOGENE NEU;

EID: 0033709674     PISSN: 10811672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (149)

1. Interaction between ERB-receptors and heregulin in breast cancer tumor progression and drug resistance
2. Amplification of C-ERB-B2 and aggressive breast tumors?
3. The neu oncogene: More than a prognostic indicator?
4. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene
5. Correlation of c-erb B2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
6. Neu-protein overexpression in breast cancer
7. Amplification of the c-erb B-2 oncogene in prognosis of breast adenocarcinoma
8. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer
9. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases
10. HER-2/neu amplification predicts poor survival in node-positive breast cancer
11. Pathologic findings from the nation's surgical adjuvant breast and bowel project: Prognostic significance of erb B2 protein overexpression in primary breast cancer
12. Immunohistochemical assay of neu/c-erb B-2 oncogene product in paraffin-embedded tissues in early breast cancer: Retrospective follow-up study of 245 stage I and II cases
13. Association of C-erb B2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer
14. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes
15. Follow-up study of HER-2/neu amplification in primary breast cancer
16. C-erb B2 oncoprotein expression in primary and advanced breast cancer
17. Prognostic significance of C-erb B2 and estrogen receptor status in human breast cancer
18. Long term survival in breast cancer related to overexpression of the C-erb B2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL-CB11
19. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors
20. The long term prognostic significance of C-erb B2 in primary breast cancer
21. The relationship between C-erb B2 expression, and s-phase fraction in prognosis in breast cancer
22. Correlation between C-erb B2 amplification and risk of recurrent disease in node-negative breast cancer
23. Prognostic significance of Her-2 oncoprotein expression in breast cancer: A 30-year follow up
24. Expression of HER-2/neu oncoprotein in breast cancer: A comparison of immunohistochemical and western blot techniques
25. c-erb B-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer
26. HER-2/neu node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in-situ carcinoma
27. Significance of c-erb B-2 amplification in DNA aneuploidy: Analysis in 78 patients with node-negative breast cancer
28. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis
29. Prognostic importance of C-erb B2 expression in breast cancer
30. Prognostic significance of C-erb B2 expression in node negative breast cancer
31. Her-2/neu expression in node-negative breast cancer: Direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease
32. Clinical significance of Her-2/neu oncogene amplification in primary breast cancer
33. Human breast cancer: Correlation study between Her-2/neu amplification and prognostic factors in an unselected population
34. Prognostic and predictive relevance of C-erb B2 and ras expression in node positive and negative breast cancer
35. Cerb-B2 expression and response to adjuvant therapy in women with node-positive early breast cancer
36. Prognostic significance of Her-2/neu oncogene expression in node-positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy
37. Prognostic value of CerbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol
38. Breast cancer response to adjuvant chemotherapy in correlation with erb B2 and p53 expression
39. Overexpression of p53 and Her-2/neu proteins as prognostic markers in early stage breast cancer
40. Immunohistochemical detection of Her-2/neu expression in patients with axillary lymph node-negative breast carcinoma: A study of epidemiologic risk factors, histologic features and prognosis
41. The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases
42. Carcinoembryonic expression in stages I and II breast cancer: Its relationship with clinicopathologic factors
43. The predictive power of semiquantitative immunohistochemical assessment of p53 and C-erbB2 in lymph node-negative breast cancer
44. Her-2/neu and p53 expression in breast cancer: Valid prognostic markers when assessed by direct immunoassay, but not by immunochemistry
45. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer
46. ErbB2 assay in breast cancer: Possibly improved clinical information using a quantitative method
47. Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: Relation with epidemiologic factors, histologic features and prognosis
48. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer
49. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival
50. Her-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
51. Multivariate analysis of prognostic factors in lymph node negative breast cancer
52. Prognostic significance of p34(cdc2) cyclin dependent kinase and MIB 1 overexpression, and HER-2/neu gene amplification detected by fluorescence in-situ hybridization in breast cancer
53. Modulation of biomarkers in minimal breast carcinoma
54. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer
55. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers
56. Prognosis and breast cancer. Recognition of lethal and favorable prognostic types
57. Overview of the biologic markers in breast cancer
58. How to use prognostic factors in axillary node-negative breast cancer patients
59. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
60. Fluorescence in-situ hybridization for detecting ERBB-2 amplification in breast tumor fine needle aspiration biopsies
61. Prognostic and predictive factors in breast cancer by immunohistochemical analysis
62. ERBB2 in breast cancer alanyzed by fluoresecence in situ hybridization
63. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization
64. Correlation between molecular genetic analyses and immunohistochemical evaluation of the epidermal growth factor receptor and p185HER2
65. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer
66. Variability of immunohistochemical reactivity on stored paraffin slides
67. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation
68. Analysis of C-erb B2 expression using a panel of six commercially available antibodies
69. Sensitivity of Her-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
70. erbB2 oncoprotein expression in breast carcinoma. Poor prognosis associated with high degree of cytoplasmic positivity using CB-antibody
71. Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens
72. A scoring system for immunohistochemical staining: Consensus report of the Task Force for Basic Research of the EORTC-GCGC
73. Quantitative analysis of p185(HER-2/neu) protein in breast cancer and its association with other prognostic factors
74. Quantitative determination of c-erbB-2 in human breast tumours: Potential prognostic significance of low values
75. HER-2/neu gene amplification status in prostate cancer by fluorescence in-situ hybridization
76. Immunohistochemical evaluation of cerb B2 oncogene expression in ductal carcinoma in-situ and atypical ductal hyperplasia of the breast
77. Overexpression of Her-2/neu and its relationship with other prognostic factors changed during progression of in-situ to invasive breast cancer
78. Mammographically-detected ductal in-situ carcinoma of the breast analyzed with a new classification
79. Prognostic variables in invasive breast cancer: Contribution of comedo versus non-comedo in-situ component
80. Ductal carcinoma in-situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53 and C erb B-2 protein
81. Ductal carcinoma in-situ: Assessment of necrosis in nuclear morphology and their association with biological markers
82. neu Overexpression correlates with extent of disease in large cell ductal in situ carcinoma of the breast
83. Differential distribution of erb B2 and pS2 proteins in ductal carcinoma in-situ of the breast
84. Biophenotypes of breast carcinoma in-situ defined by image analysis of biological parameters
85. Immunophenotype of intraductal carcinoma
86. Ductal carcinoma in-situ of the breast: Correlation between histologic classification and biologic markers
87. Relationship of a new histological categorization of ductal carcinoma in-situ of the breast with size and the immunohistochemical expression of p53, C-erb B2, bc12 and ki-67
88. cerb B2 oncogene protein in in-situ and invasive lobular breast neoplasia
89. HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular breast cancer
90. Expression of cerb B2 oncoprotein in mammary and extramammary Paget's disease
91. cerb B2 protein and neuroendocrine expression in intraductal carcinomas of the breast
92. Expression of erb B2 gene in the benign and proliferative breast tissue
93. Distribution and patterns of staining of neu oncogene product in benign and malignant breast diseases
94. Reduction of Telomeric-linked cerb B2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia: Relationship to histologic grade and clinical parameters
95. Prognostic factors for carcinoma of the male breast
96. Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome
97. Male breast cancer: Pathological and immunohistochemical features
98. C-erb and p53 overexpression as predictors of survival in patients with male breast cancer
99. Male breast cancer: Clinicopathological features, immunocytochemical characteristics and prognosis
100. Immunocytochemical characterization of male breast cancer
101. Relationship between C-ERBB 2 protein product expression and response to endocrine therapy in advanced to breast cancer
102. Elevated serum C-erb B2 antigen levels and decreased response to hormone therapy of breast cancer
103. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
104. C-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
105. Expression of ras p21, p53 and C-erb B2 in advanced breast cancer and response to line hormonal therapy
106. Overexpression of cerbB2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms
107. CerbB2 overexpression decreases the benefit of adjuvant Tamoxifen in early-stage breast cancer without ancillary lymph node metastases
108. Evaluation of HER-2/neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study
109. Plasma CerbB2 concentrations in relations to chemotherapy in breast cancer patients
110. HER-2 overexpression and paclitazel sensitivity in breast cancer: Therapeutic implications
111. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
112. Expression of epidermal growth factor receptor and C-erb B2 during the development of tamoxifen resistance in human breast cancer
113. Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma
114. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
115. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A southwest oncology group study
116. Overexpression of both p 185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol
117. 20 Year update of the Naples Gun trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and tamoxifen efficacy
118. Initial report of the SWOG biological correlative study of c-ERBB2 expression as a predictor of outcome in a trial comparing adjuvant CAF with Tamoxifen alone
119. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer
120. Elevated erb B-2 oncoprotein levels in preoperative and follow-up serum samples defined in aggressive course in patients with breast cancer
121. Soluable c-erb B-2 fragments in serum correlates with disease stage and predicts more shortened survival in patients with early-stage and advanced breast cancer
122. Measurement of C-erb B2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: Correlation with serum tumor markers and membrane-bound oncoproteins
123. Detection of C-erb B2 related proteins in sera from breast cancer patients: Relationship to ERBB2 gene amplification and Cerb B2 protein overexpression in tumour
124. Serial serum C-erbB-2 levels in patients with breast carcinoma
125. Utility of cerbB2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: Comparison with carcinoembryonic antigen and CA15.3
126. Prognostic significance of serum CerbB2 protein in breast cancer patients
127. Influence of circulating C-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients
128. Tissue in serum CerbB2 and tissue EGFR in breast carcinoma: Three years follow-up
129. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer
130. Tissue expression and serum levels of HER-2/neu in patients with breast cancer
131. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer
132. Plasma c-erbB-2 levels in breast cancer patients: Prognostic significance in predicting response to chemotherapy
133. Monoclonal antibody therapy of human cancer: Taking the Her-2 proto-oncogene to the clinic
134. Suppressed transformation and induced differentiation of Her-2/neu - Overexpressing breast cancer cells by emodin
135. Effectiveness of an adriamycin immunoconjugate that recognizes the CerbB2 product on breast cancer cell lines
136. Inhibition of erbB2 positive breast cancer cell growth by erbB2 antisense oligonucleotides
137. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2
138. The clinical studies with Fc (Gamma) R by specific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpression in breast cancer
139. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody
140. Recombinant humanized anti-HER2 (Herceptin(TM)) enhances the antitumor activity of paclitaxel and doxorubicin against HER-2/neu overexpressing human breast cancer xenografts
141. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humeral immune response against HER2-expressing murine sarcomas
142. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu
143. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu
144. Phase II study of weekly intravenous recombinant humanized anti p185 Her-2 monoclonal antibody in patients with Her-2/neu overexpressing metastatic breast cancer
145. Efficacy and safety of Herceptin(R) (humannized anti-human HER-2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
146. Addition of Herceptin(R) (humanized anti HER2 antibody) to first line chemotherapy for HER2 overexpressing metatstatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phase III trial
147. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes
148. HER-2/neu peptide vaccines ellicit T cell immunity to the HER-2/neu protein in patients with breast and ovarian cancer
149. Clinicoradioimmunolocalization with a rat monoclonal antibody directed against C-erb B2